Jon Soderstrom has spent the last quarter-century waiting for Greater New Haven’s bioscience industry to catch up with his vision.
Since being recruited to lead Yale’s Office of Cooperative Research in 1996, Soderstrom has played a leading role in building an ecosystem that he hoped would one day put New Haven on the map as a nationally recognized biotech hub.
It appears to him that moment is about to arrive. Consider the evidence, he said, ticking off a list of recent headlines.
- A $93 million IPO for rare disease biotech Rallybio.
- AstraZeneca’s eye-popping $39 billion buyout of Alexion Pharmaceuticals.
- The Wall Street debut of two medtech startups launched by bioscience entrepreneur Jonathan Rothberg.
- Pfizer’s $1 billion investment in Arvinas’ experimental breast cancer drug.
- A developer breaking ground on a new downtown bioscience tower.
“People used to laugh and say ‘How are you going to do all this stuff?’ ” Soderstrom said in a recent Zoom interview from his home office in Madison. “And now it’s actually happening.”
Read More